Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
A ZnS-SnS-NiCoS composite was fabricated on Ni foam by polymetallic compositing of NiS. The optimized catalyst exhibits outstanding OER performance with a low overpotential (149 mV at 10 mA cm) and Tafel slope (33.57 mV dec), offering a promising strategy for efficient water splitting and sustainable hydrogen production.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/d5cc03159a | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antiferroelectric SnO Network with Amorphous Surface for Electrochemical N Fixation.
Angew Chem Int Ed Engl
September 2025
State Key Laboratory of Bioinspired Interfacial Materials Science, Bioinspired Science Innovation Center, Hangzhou International Innovation Institute, Beihang University, Hangzhou, 311115, China.
Electrochemical nitrogen fixation-a sustainable pathway for converting abundant N into NH using renewable energy-holds transformative potential for revolutionizing artificial nitrogen cycles. Nevertheless, even the state-of-the-art catalytic systems also suffer from inadequate N adsorption capacity, which critically limits ammonia production rates and Faradaic efficiency (FE). To overcome this bottleneck, we strategically leveraged the antiferroelectric properties of SnO to establish dipole-dipole interactions with N molecules, synergistically enhancing both N adsorption and activation kinetics.
View Article and Find Full Text PDFDevelopment and evaluation of pupal color-based genetic sexing strains in Anastrepha obliqua (Diptera: Tephritidae).
Insect Sci
September 2025
Programa Operativo Moscas, SADER/SENASICA-IICA, Metapa de Domínguez, Chiapas, Mexico.
Anastrepha obliqua, a neotropical pest widely distributed in the Americas, attacks mango and other tropical fruits. In Mexico, it is controlled through integrated pest management, using the Sterile Insect Technique (SIT) as a main component. The applicability of SIT is significantly improved with the use of genetic sexing strains (GSS) that allow the possibility to release exclusively sterile males, the primary component of the technique.
View Article and Find Full Text PDFAntibody Therapies for Alzheimer's Disease: A New Strategy for Targeted Therapy and Blood-Brain Barrier Delivery.
ACS Chem Neurosci
September 2025
Institute of Cell Engineering, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21215, United States.
Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive impairment and neuronal loss, with pathological hallmarks including Aβ plaque deposition and tau tangles. At present, the early diagnosis and treatment of AD still face great challenges, such as limited diagnostic methods, difficulty in blood-brain barrier (BBB) penetration, complex disease mechanisms, and lack of highly effective targeted therapies. Antibody drugs have shown broad prospects in the field of AD due to their high specificity, engineering and multifunctional therapeutic potential, include targeted Aβ clearance, tau pathological regulation, imaging probes, and blood biomarkers.
View Article and Find Full Text PDFUnlocking new frontiers: novel immune targets for next-generation cancer immunotherapy.
Korean J Clin Oncol
August 2025
Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
Cancer immunotherapy represents a transformative strategy in modern oncology, utilizing the body's immune system to recognize and eliminate malignant cells with precision. Unlike traditional therapies, which often directly target the tumor, immunotherapy enhances the immune system's inherent ability to differentiate between healthy and cancerous cells. The advent of immune checkpoint inhibitors (ICIs), particularly those targeting the PD-1/PD-L1 and CTLA-4 pathways, has marked a significant breakthrough in this field.
View Article and Find Full Text PDFSafety, immunogenicity and efficacy of the Shingrix vaccine in immunocompromised varicella zoster virus naïve pediatric patients.
Vaccine
September 2025
Department of Paediatric Immunology and Rheumatology, Wilhelmina Children's Hospital/ University Medical Center Utrecht, Utrecht, the Netherlands; Faculty of Medicine, Utrecht University, Utrecht, the Netherlands.
Background: Pediatric patients with autoimmune and inflammatory diseases often require immunosuppressive therapy, which increases their susceptibility to infections, including varicella-zoster virus (VZV). While the live attenuated varicella vaccine is contraindicated in most immunocompromised children, the recombinant subunit vaccine, Shingrix, may offer an alternative preventive strategy. However, data on its safety, immunogenicity, and efficacy in pediatric VZV-naïve patients remain limited.
View Article and Find Full Text PDF